May. 14 at 11:52 PM
$BFRI Honestly solid Earnings Call, I genuinely expected a lot less from Q1. Some key things worth noting:
Cash used in operations this quarter was only
$70,000 compared to
$4.1 million in Q1 2025.
Current Cash Balance stands at
$6.3 million as of March 31st, 2026 vs
$6.4 million as of December 31st, 2025.
Revenue grew 17% YoY to
$10.1 million.
Gross margin jumped to ~80% (from ~62% last year).
Near-term label expansions remain on track.
sBCC PDUFA target action date still September 28th, 2026.
AK on trunk/extremities sNDA planned for Q3 2026.
Acne program: Phase 3 design meeting with FDA set for H2 2026.
As of May 6th, 2026, we have regained Nasdaq Compliance.
Biofrontera is the only company in the U.S. actively running FDA-controlled clinical studies in PDT for dermatology, with patent protection extending through 2043.
Path to cash-flow breakeven in full-year 2026 has been reiterated (supported by continued revenue growth,
$1M Xepi milestone, and potential credit facility).
